Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of plasma concentration of Imatinib in Chinese patients with gastrointestinal stromal tumor

Trial Profile

Study of plasma concentration of Imatinib in Chinese patients with gastrointestinal stromal tumor

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 30 Apr 2017 Status changed from not yet recruiting to completed.
    • 22 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
    • 22 Apr 2016 Phase of the study is changed from phase I to phase IV.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top